Recent research has resulted in a very rich pipeline of new agents to treat migraine, said David Dodick, MD, in presenting the Global Year Against Pain Lecture at the American Pain Society’s 31st Annual Scientific Meeting.
Legislation recently enacted in the State of Washington to moderate opioid dosing in light of a 240% increase in deaths between 2001 and 2009 is placing physicians in the position of negotiating with patients with chronic noncancer pain to taper doses, a panel of physicians noted during the American Pain Society’s 31st Annual Scientific Meeting.
Using nano-formulated, lower-dose NSAIDs may provide clinical benefit for relieving mild to moderate acute pain, reported Garen Manvelian, MD, with Iroko Pharmaceuticals, Philadelphia, PA, at the American Pain Society’s 31st Annual Scientific Meeting.
At the American Pain Society’s 31st Annual Scientific Meeting, study investigators presented data indicating that high dosages of oxymorphone extended-release (ER) appear to be generally well tolerated in patients with chronic noncancer pain.
Flurbiprofen 8.75mg lozenge provides lasting relief of pharyngeal pain, noted Dr. Bernard Schachtel, from New York University, New York, NY, at the American Pain Society’s 31st Annual Scientific Meeting.
At the American Pain Society’s 31st Annual Scientific Meeting, investigators reported that a 5-minute application of NGX-1998, a novel liquid formulation of high concentration capsaicin (10% and 20% w/w) provided effective pain relief for up to 12 weeks for the management of peripheral neuropathic pain associated with postherpetic neuralgia (PHN).
“Significant, clinically meaningful improvements in spontaneous bowel movement (SBM) frequency were observed after CB-5945 treatment,” stated Lee Techner, DPM, from Cubist Pharmaceuticals, Lexington, MA at the American Pain Society’s 31st Annual Scientific Meeting.
Panadol Advance (paracetamol; fast-absorbing) 1,000mg tablets were more efficacious and demonstrated faster onset and longer duration of pain relief compared with Panadol Advance 500mg, standard paracetamol 650mg, and placebo, reported Yong Yue, MD, from Jean Brown Research, Salt Lake City, UT at the American Pain Society’s 31st Annual Scientific Meeting.
In patients with postherpetic neuralgia (PHN), once-daily gabapentin 1,800mg improved all pain scores, as well as sleep and enjoyment of life interference scales, reported Misha Backonja, MD, from Lifetree Clinical Research, Salt Lake City, UT, and colleagues at the American Pain Society’s 31st Annual Scientific Meeting.
Diclofenac sodium 1% gel is well tolerated for up to 1 year for the relief of osteoarthritis (OA) pain in patients both <65 years and ≥65 years of age, according to 12-month data presented at the American Pain Society's 31st Annual Scientific Meeting.
Please login or register first to view this content.
